Expression of lipoprotein-associated phospholipase A2 in carotid artery plaques predicts long-term cardiac outcome

European Heart Journal

Volumn 30, Issue 23, 2009, Pages 2930-2938

  Herrmann, Joerg ^a   Mannheim, Dallit ^a   Wohlert, Christine ^a   Versari, Daniele ^a   Meyer, Fredric B ^a   McConnell, Joseph P ^a   Gössl, Mario ^a   Lerman, Lilach O ^a   Lerman, Amir ^a  

^a Mayo Clinic   (United States)

Author keywords

Arteriosclerosis; Cardiovascular diseases; Plaque; Prognosis

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; COLLAGEN; GELATINASE A; GELATINASE B; LYSOPHOSPHATIDYLCHOLINE; PROTEIN P67;

ACUTE HEART INFARCTION; AGED; ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CAROTID ARTERY; CAROTID ENDARTERECTOMY; COHORT ANALYSIS; DIABETES MELLITUS; ELECTIVE SURGERY; FAMILY HISTORY; FEMALE; FOLLOW UP; GENE EXPRESSION REGULATION; HEART DEATH; HISTOLOGY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOBLOTTING; LIQUID CHROMATOGRAPHY; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; SMOKING; TANDEM MASS SPECTROMETRY;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AGED; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CAROTID ARTERIES; CAROTID STENOSIS; ENDARTERECTOMY, CAROTID; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; LYSOPHOSPHATIDYLCHOLINES; MACROPHAGES; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; PHOSPHOPROTEINS;

EID: 71549159171     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehp309     Document Type: Article

References (36)

1. Ouriel K. Peripheral arterial disease. Lancet 2001;358:1257-1264.
2. Lombardo A, Biasucci LM, Lanza GA, Coli S, Silvestri P, Cianflone D, Liuzzo G, Burzotta F, Crea F, Maseri A. Inflammation as a possible link between coronary and carotid plaque instability. Circulation 2004;109:3158-3163.
3. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon JJ, Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone PH, Waxman S, Raggi P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald PJ, Siscovick DS, de Korte CL, Aikawa M, Juhani Airaksinen KE, Assmann G, Becker CR, Chesebro JH, Farb A, Galis ZS, Jackson C, Jang IK, Koenig W, Lodder RA, March K, Demirovic J, Navab M, Priori SG, Rekhter MD, Bahr R, Grundy SM, Mehran R, Colombo A, Boerwinkle E, Ballantyne C, Insull W Jr, Schwartz RS, Vogel R, Serruys PW, Hansson GK, Faxon DP, Kaul S, Drexler H, Greenland P, Muller JE, Virmani R, Ridker PM, Zipes DP, Shah PK, Willerson JT. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I. Circulation 2003;108:1664-1672. (Pubitemid 37243650)
4. Libby P. Atherosclerosis: disease biology affecting the coronary vasculature. Am J Cardiol 2006;98:3Q-9Q.
5. MacPhee C, Moores K, Boyd H, Dhanak D, Ife R, Leach C, Leake D, Milliner K, Patterson R, Suckling K, Tew D, Hickey D. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J 1999;338:479-487.
6. Shi Y, Zhang P, Zhang L, Osman H, Mohler ER III, Macphee C, Zalewski A, Postle A, Wilensky RL. Role of lipoprotein-associated phospholipase A2 in leukocyte activation and inflammatory responses. Atherosclerosis 2007;191:54-62.
7. Stocker R, Keaney JF Jr. New insights on oxidative stress in the artery wall. J Thromb Haemost 2005;3:1825-1834.
8. Lavi S, Lavi R, McConnell JP, Lerman LO, Lerman A. Lipoprotein-associated phos-pholipase A(2): review of its role as a marker and a potential participant in coronary endothelial dysfunction. Mol Diagn Ther 2007;11:219-226.
9. Lavi S, McConnell JP, Rihal CS, Prasad A, Mathew V, Lerman LO, Lerman A. Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcho-line in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans. Circulation 2007;115:2715-2721.
10. Kolodgie FD, Burke AP, Skorija KS, Ladich E, Kutys R, Makuria AT, Virmani R. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2006; 26:2523-2529.
11. MannheimD,HerrmannJ,VersariD,GosslM,Meyer FB, McConnell JP, Lerman LO, Lerman A. Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques. Stroke 2008;39:1448-1455.
12. Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. J Am Coll Cardiol 2007;50:2173-2195. (Pubitemid 350123680)
13. Versari D, Herrmann J, Gossl M, Mannheim D, Sattler K, Meyer FB, Lerman LO, Lerman A. Dysregulation of the ubiquitin-proteasome system in human carotid atherosclerosis. Arterioscler Thromb Vasc Biol 2006;26:2132-2139.
14. Brilakis ES, McConnell JP, Lennon RJ, Elesber AA, Meyer JG, Berger PB. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J 2005;26:137-144.
15. Kardys I, Oei H-HS, van der Meer IM, Hofman A, Breteler MMB, Witteman JCM. Lipoprotein-associated phospholipase A2 and measures of extracoronary atherosclerosis: the Rotterdam study. Arterioscler Thromb Vasc Biol 2006;26:631-636.
16. Yang EH, McConnell JP, Lennon RJ, Barsness GW, Pumper G, Hartman SJ, Rihal CS, Lerman LO, Lerman A. Lipoprotein-associated phospholipase A2 is an independent marker for coronary endothelial dysfunction in humans. Arterios-cler Thromb Vasc Biol 2006;26:106-111.
17. Packard CJ, O'Reilly DSJ, Caslake MJ, McMahon AD, Ford I, Cooney J, Macphee CH, Suckling KE, Krishna M, Wilkinson FE, Rumley A, Lowe GDO, Docherty G, Burczak JD, The West of Scotland Coronary Prevention Study Group. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. N Engl J Med 2000;343:1148-1155.
18. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G, Sharrett AR. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the atherosclerosis risk in communities (ARIC) study. Circulation 2004;109:837-842.
19. Koenig W, Khuseyinova N, Lowel H, Trischler G, Meisinger C. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation 2004;110:1903-1908.
20. Oei H-HS, van der Meer IM, Hofman A, Koudstaal PJ, Stijnen T, Breteler MMB, Witteman JCM. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam study. Circulation 2005;111:570-575.
21. Quinn MT, Parthasarathy S, Steinberg D. Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc Natl Acad Sci USA 1988;85:2805-2809.
22. Hakkinen T, Luoma JS, Hiltunen MO, Macphee CH, Milliner KJ, Patel L, Rice SQ, Tew DG, Karkola K, Yla-Herttuala S. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1999;19:2909-2917.
23. Rong JX, Berman JW, Taubman MB, Fisher EA. Lysophosphatidylcholine stimulates monocyte chemoattractant protein-1 gene expression in rat aortic smooth muscle cells. Arterioscler Thromb Vasc Biol 2002;22:1617-1623.
24. Chai YC, Howe PH, DiCorleto PE, Chisolm GM. Oxidized low density lipopro-tein and lysophosphatidylcholine stimulate cell cycle entry in vascular smooth muscle cells. Evidence for release of fibroblast growth factor-2. J Biol Chem 1996;271:17791-17797.
25. Hsieh CC, Yen MH, Liu HW, Lau YT. Lysophosphatidylcholine induces apoptotic and non-apoptotic death in vascular smooth muscle cells: in comparison with oxidized LDL. Atherosclerosis 2000;151:481-491.
26. Takahashi M, Okazaki H, Ogata Y, Takeuchi K, Ikeda U, Shimada K. Lysophosphatidyl-choline induces apoptosis inhuman endothelial cells throughap38-mitogen-activated protein kinase-dependent mechanism. Atherosclerosis 2002;161:387-394.
27. Inoue N, Takeshita S, Gao D, Ishida T, Kawashima S, Akita H, Tawa R, Sakurai H, Yokoyama M. Lysophosphatidylcholine increases the secretion of matrix metallo-proteinase 2 through the activation of NADH/NADPH oxidase in cultured aortic endothelial cells. Atherosclerosis 2001;155:45-52.
28. Barcellos-Hoff MH, Dix TA. Redox-mediated activation of latent transforming growth factor-beta 1. Mol Endocrinol 1996;10:1077-1083.
29. Hellings WE, Peeters W, Moll FL, Pasterkamp G. From vulnerable plaque to vulnerable patient: the search for biomarkers of plaque destabilization. Trends Cardi-ovasc Med 2007;17:162-171. (Pubitemid 46898844)
30. Johnsen SH, Mathiesen EB, Joakimsen O, Stensland E, Wilsgaard T, Lochen ML, Njolstad I, Arnesen E. Carotid atherosclerosis is a stronger predictor of myocar-dial infarction in women than in men: a 6-year follow-up study of 6226 persons: the Tromso study. Stroke 2007;38:2873-2880.
31. Goessens BM, Visseren FL, Kappelle LJ, Algra A, van der Graaf Y. Asymptomatic carotid artery stenosis and the risk of new vascular events in patients with manifest arterial disease: the SMART study. Stroke 2007;38:1470-1475.
32. Rothwell PM, Villagra R, Gibson R, Donders RC, Warlow CP. Evidence of a chronic systemic cause of instability of atherosclerotic plaques. Lancet 2000;355:19-24.
33. Serruys PW, Garcia-Garcia HM, Buszman P, Erne P, Verheye S, Aschermann M, Duckers H, Bleie O, Dudek D, Botker HE, von Birgelen C, D'Amico D, Hutchinson T, Zambanini A, Mastik F, van Es GA, van der Steen AF, Vince DG, Ganz P, Hamm CW, Wijns W, Zalewski A. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 2008;118:1172-1182.
34. Shi Y, Zalewski A, Macphee CH, Dawson M. Selective inhibition of lipoprotein-associated phospholipase A2 attenuates markers of plaque vulnerability in humans. Circulation 2007;116:1.
35. Wilensky RL, Shi Y, Mohler ER III, Hamamdzic D, Burgert ME, Li J, Postle A, Fenning RS, Bollinger JG, Hoffman BE, Pelchovitz DJ, Yang J, Mirabile RC, Webb CL, Zhang L, Zhang P, Gelb MH, Walker MC, Zalewski A, Macphee CH. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nature Med 2008;14:1059-1066.
36. Atik B, Johnston SC, Dean D. Correlation of lipoprotein-associated phospho-lipase A2 serum activity and tissue protein (Lp-PLA2) with carotid tissue macro-phages and Chlamydophila pneumoniae infection among patients at tisk for stroke. Stroke 2008;39:716.